HEART FAILURE: Edited by Haissam HaddadCardiovascular complications following pneumonia focus on pneumococcus and heart failureBartlett, Benjamina,b; Ludewick, Herbert P.b; Lee, Silviaa,b,c; Dwivedi, Girisha,b,dAuthor Information aFaculty of Health and Medical Sciences, Medical School, The University of Western Australia, Perth bDepartment of Advanced Clinical and Translational Cardiovascular Imaging, Harry Perkins Institute of Medical Research, Murdoch cDepartment of Microbiology, Pathwest Laboratory Medicine, Perth dDepartment of Cardiology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia Correspondence to Girish Dwivedi, MD, PhD, MRCP, FASE, FESC, FRACP, Harry Perkins Institute of Medical Research and Fiona Stanley Hospital, The University of Western Australia, Perth, WA 6009, Australia. Tel: +61 8 6151 0000; e-mail: [email protected] Current Opinion in Cardiology: March 2019 - Volume 34 - Issue 2 - p 233-239 doi: 10.1097/HCO.0000000000000604 Buy Metrics Abstract Purpose of review Pneumonia, an inflammatory disease, is the single largest infectious cause of death. Pneumonia has recently been established as an important contributing factor to major adverse cardiovascular events including heart failure. Developing an intermechanistic understanding of pneumonia and cardiovascular disease is crucial for successful future drug therapy and reducing healthcare expenditure. Recent findings Up to 30% of patients admitted with pneumonia develop cardiovascular complications such as heart failure within 10 years of hospital discharge. Recent mechanistic studies have identified inflammation, pneumolysin, platelet activation, and thrombus formation at the center of cardiovascular disease progression. Summary In this review, we will detail current knowledge of the mechanistic interaction between pneumonia and development of cardiovascular disease as well as discuss the current and potential drug therapy targets. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.